ClinicalTrials.gg
CompletedNCT02305238ALTAIRUpdated Nov 18, 2023Results posted

Japanese Treat and Extend Study of Aflibercept in Neovascular Age-related Macular Degeneration

A Phase 4 interventional study of Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) in Wet Macular Degeneration, sponsored by Bayer. Completed at 41 sites in Japan. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2023-11-18.

Sponsored by Bayer · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
288
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Study summary

To assess the efficacy of intravitreal (IVT) administration of aflibercept with two different approaches of Treat and Extend dosing regimens in Japanese subjects with neovascular (wet) Age-related Macular Degeneration (wAMD) .

To assess the safety of IVT administration of aflibercept with two different approaches of Treat and Extend dosing regimen in Japanese subjects with wAMD for up to 2 years.

02

Conditions studied

  • Wet Macular Degeneration

Keywords

  • Eylea,
  • Aflibercept
  • Treat and Extend regimen
  • Age-related macular degeneration
03

In context

Wet Macular Degeneration

93 studies on the registry are indexed under Wet Macular Degeneration; 10 are open to participants now.

This study's enrollment of 288 is above the median of 101 across 74 interventional studies indexed under Wet Macular Degeneration.

Browse Wet Macular Degeneration studies →

Lead sponsor

Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.

Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Japanese men and women ≥ 50 years of age
  • Active primary subfoveal choroidal neovascularization (CNV) lesions secondary to wAMD, including juxta-foveal lesions that affect the fovea as evidenced by fluorescein angiography (FA) in the study eye
  • Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA) of 73 to 25 letters (approximately 20/40 to 20/320 at Snellen equivalent) in the study eye

Exclusion criteria

Exclusion Criteria:

  • Prior treatment of the study eye with intraocular anti-VEGF(Vascular Endothelial Growth Factor) agents, verteporfin photodynamic therapy (PDT), other laser, intraocular , surgical interventions (except cataract surgery more than 30 days prior to screening) or systemic use of anti-VEGF products within 3 months prior to study entry
  • Active or suspected infection in or surrounding of the study eye
  • Active severe intraocular inflammation in the study eye
  • Intraocular pressure (IOP) ≥ 25 mmHg in the study eye
  • Ocular condition in the study eye which may impact vision and confound study outcomes
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
288 participants (actual)

Study arms

  • Experimental
    2 Weeks adjustment

    Participants received Aflibercept IVT injection at Week 0, Week 4, Week 8 and Week 16 followed by the variable treatment intervals with the criteria of Treat and Extend regimen. In the case the study eye of a participant met the criteria, the length of treatment interval was to be extended or shortened by 2 weeks from the last interval, respectively. Minimum/Maximum treatment interval is 8 weeks and 16 weeks during Week 16 to 96.

    Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

  • Experimental
    4 Weeks adjustment

    Participants received Aflibercept IVT injection at Week 0, Week 4, Week 8 and Week 16 followed by the variable treatment intervals. In the case the study eye of a participant met the criteria of the shortening, the length of the treatment interval was to be shortened by 2 weeks. But when the last treatment interval for a participant was extended by 4 weeks from the second last interval, the treatment interval was shortened by 4 weeks. In the case the study eye of a participant met the criteria of the extension, the length of the treatment interval was to be extended by 4 weeks. But when a participant had a history of receiving treatment with interval shortened by 4 weeks during this study, the length of the extension was 2 weeks. Minimum/Maximum treatment interval is 8 weeks and 16 weeks during Week 16 to 96.

    Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in BCVA at Week 52

    Visual functions of the study eye (at every visit) and the fellow eye were assessed, according to the ETDRS protocol as described in detail in the operation manual. A higher score represents better functioning.

    Time frame: Baseline and Week 52

Secondary outcomes

  1. Percentage of Participants Who Maintained Vision at Week 52

    A participant was classified as maintaining vision if the participant had lost fewer than 15 letters in the ETDRS letter score compared to baseline.

    Time frame: Week 52

  2. Percentage of Participants Who Gained at Least 15 Letters of Vision Compared to Baseline at Week 52

    Time frame: Baseline and Week 52

  3. Mean Change in Central Retinal Thickness (CRT) From Baseline at Week 52

    Time frame: Baseline and week 52

  4. Percentage of Participants Without Fluid on Optical Coherence Tomography (OCT) at Week 52

    A participant was classified as without fluid if "Evidence of new or persistent fluid" on OCT was "No".

    Time frame: Week 52

07

Results

Posted Mar 12, 2018

Participant flow

Study was conducted in Japan between 19 December 2014 (first participant first visit) and 08 November 2017 (last participant last visit).

Participant flow — Overall Study
Milestone2 Weeks Adjustment4 Weeks AdjustmentRandomization Failure
Started1241238
Treated1241237
Randomized1241230
Bcva post-randomization assessment1231230
Completed1081040
Not completed16198
Withdrew: Death210
Withdrew: Progressive disease440
Withdrew: Logistical difficulties130
Withdrew: Protocol violation030
Withdrew: Physician decision210
Withdrew: Adverse event420
Withdrew: Withdrawal by subject340
Withdrew: Randomized failure008
Withdrew: Required procedure failed010

Outcome measures

PrimaryMean Change From Baseline in BCVA at Week 52

Visual functions of the study eye (at every visit) and the fellow eye were assessed, according to the ETDRS protocol as described in detail in the operation manual. A higher score represents better functioning.

Time frame:
Baseline and Week 52
Reported as:
Mean · letters
Mean Change From Baseline in BCVA at Week 52
letters2 Weeks Adjustment4 Weeks Adjustment
Mean Change From Baseline in BCVA at Week 529.0 ± 14.68.4 ± 13.4
Statistical analysis
  • 2 Weeks Adjustment vs 4 Weeks Adjustment · Least square (ls) mean difference: -0.4 · 95% CI -3.8 to 3.0
SecondaryPercentage of Participants Who Maintained Vision at Week 52

A participant was classified as maintaining vision if the participant had lost fewer than 15 letters in the ETDRS letter score compared to baseline.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Maintained Vision at Week 52
percentage of participants2 Weeks Adjustment4 Weeks Adjustment
Percentage of Participants Who Maintained Vision at Week 5296.7 (93.6 to 99.9)95.9 (92.4 to 99.4)
Statistical analysis
  • 2 Weeks Adjustment vs 4 Weeks Adjustment · Mantel-haenszel (mh) adjusted difference: -0.9 · 95% CI -5.7 to 4.0
SecondaryPercentage of Participants Who Gained at Least 15 Letters of Vision Compared to Baseline at Week 52
Time frame:
Baseline and Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Gained at Least 15 Letters of Vision Compared to Baseline at Week 52
percentage of participants2 Weeks Adjustment4 Weeks Adjustment
Percentage of Participants Who Gained at Least 15 Letters of Vision Compared to Baseline at Week 5232.5 (24.2 to 40.8)30.9 (22.7 to 39.1)
Statistical analysis
  • 2 Weeks Adjustment vs 4 Weeks Adjustment · Mh adjusted difference: -1.4 · 95% CI -12.7 to 9.8
SecondaryMean Change in Central Retinal Thickness (CRT) From Baseline at Week 52
Time frame:
Baseline and week 52
Reported as:
Mean · μm
Mean Change in Central Retinal Thickness (CRT) From Baseline at Week 52
μm2 Weeks Adjustment4 Weeks Adjustment
Mean Change in Central Retinal Thickness (CRT) From Baseline at Week 52-134.4 (-162.2 to -106.6)-126.1 (-147.1 to -105.1)
Statistical analysis
  • 2 Weeks Adjustment vs 4 Weeks Adjustment · Ls mean difference: -5.8 · 95% CI -24.3 to 12.7
SecondaryPercentage of Participants Without Fluid on Optical Coherence Tomography (OCT) at Week 52

A participant was classified as without fluid if "Evidence of new or persistent fluid" on OCT was "No".

Time frame:
Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants Without Fluid on Optical Coherence Tomography (OCT) at Week 52
Percentage of participants2 Weeks Adjustment4 Weeks Adjustment
Percentage of Participants Without Fluid on Optical Coherence Tomography (OCT) at Week 5268.3 (60.1 to 76.5)69.1 (60.9 to 77.3)
Statistical analysis
  • 2 Weeks Adjustment vs 4 Weeks Adjustment · Mh adjusted difference: 1.0 · 95% CI -10.6 to 12.7

Adverse events

Collected over Up to 96 weeks. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
2 Weeks Adjustment—19/124 (15.3%)49/124 (39.5%)
4 Weeks Adjustment—20/123 (16.3%)61/123 (49.6%)
Randomization Failure—3/7 (42.9%)4/7 (57.1%)
Most frequent serious events
Showing 10 of 40
Most frequent serious events
Event2 Weeks Adjustment4 Weeks AdjustmentRandomization Failure
PneumoniaInfections and infestations0/1240/1232/7
Cholecystitis acuteHepatobiliary disorders0/1240/1231/7
CataractEye disorders4/1245/1230/7
CholelithiasisHepatobiliary disorders2/1241/1230/7
Acute myocardial infarctionCardiac disorders0/1241/1230/7
Angina pectorisCardiac disorders0/1241/1230/7
Coronary artery stenosisCardiac disorders0/1241/1230/7
TachycardiaCardiac disorders0/1241/1230/7
Sinus node dysfunctionCardiac disorders0/1241/1230/7
IleusGastrointestinal disorders0/1241/1230/7
Most frequent other events
Showing 10 of 26
Most frequent other events
Event2 Weeks Adjustment4 Weeks AdjustmentRandomization Failure
NasopharyngitisInfections and infestations26/12420/1230/7
Atrial fibrillationCardiac disorders0/1240/1231/7
ToothacheGastrointestinal disorders1/1241/1231/7
Oedema peripheralGeneral disorders1/1241/1231/7
Cholecystitis acuteHepatobiliary disorders0/1240/1231/7
ArthritisMusculoskeletal and connective tissue disorders0/1241/1231/7
Joint swellingMusculoskeletal and connective tissue disorders0/1240/1231/7
HypertensionVascular disorders1/1244/1231/7
CataractEye disorders5/12410/1230/7
Conjunctival haemorrhageEye disorders4/1248/1230/7

Baseline characteristics

Safety analysis set (SAF): included all subjects who received any study drug

Age, Continuous
Age, Continuous(years)2 Weeks Adjustment4 Weeks AdjustmentRandomization FailureTotal
Mean73.0 ± 7.975.0 ± 8.180.3 ± 7.874.2 ± 8.1
Sex: Female, Male
Sex: Female, Male(Participants)2 Weeks Adjustment4 Weeks AdjustmentRandomization FailureTotal
Female3632169
Male88916185
Best-corrected visual acuity (BCVA)
Best-corrected visual acuity (BCVA)(letters)2 Weeks Adjustment4 Weeks AdjustmentRandomization FailureTotal
Mean54.6 ± 13.155.3 ± 12.054.9 ± 17.955.0 ± 12.7
Central Retinal Thickness
Central Retinal Thickness(μm)2 Weeks Adjustment4 Weeks AdjustmentRandomization FailureTotal
Mean386.5 ± 158.6370.3 ± 120.0371.6 ± 88.5378.3 ± 139.4
Choroidal neovascularization
Choroidal neovascularization(Participants)2 Weeks Adjustment4 Weeks AdjustmentRandomization FailureTotal
No CNV0101
Classic CNV3542178
Classic & Occult1517234
Occult72624138
Unknown2103
Typical age-related macular degeneration
Typical age-related macular degeneration(Participants)2 Weeks Adjustment4 Weeks AdjustmentRandomization FailureTotal
Missing2002
No4648296
Yes76755156
Polypoidal Choroidal Vasculopathy
Polypoidal Choroidal Vasculopathy(Participants)2 Weeks Adjustment4 Weeks AdjustmentRandomization FailureTotal
Missing2002
No76795160
Yes4644292
Retinal Angiomatous Proliferation
Retinal Angiomatous Proliferation(Participants)2 Weeks Adjustment4 Weeks AdjustmentRandomization FailureTotal
Missing2002
No1181146238
Yes49114
08

Study locations

41 sites
  • Ichinomiya, Aichi 491-8551, Japan
  • Nagoya, Aichi 457-8510, Japan
  • Nagoya, Aichi 467-8602, Japan
  • Toyoake, Aichi 470-1192, Japan
  • Asahi, Chiba 289-2511, Japan
  • Sakura, Chiba 285-8741, Japan
  • Koriyama, Fukushima 963-8052, Japan
  • Kure, Hiroshima 737-0029, Japan
  • Sapporo, Hokkaido 001-0016, Japan
  • Sapporo, Hokkaido 060-0010, Japan
  • Sapporo, Hokkaido 065-0031, Japan
  • Kobe, Hyogo 650-0047, Japan
  • Inashiki-gun, Ibaraki 300-0395, Japan
  • Mito, Ibaraki 310-0845, Japan
  • Morioka, Iwate 020-8505, Japan
  • Yokohama, Kanagawa 232-0024, Japan
  • Nankoku, Kochi 783-8505, Japan
  • Miyakonojo, Miyazaki 885-0051, Japan
  • Iida, Nagano 395-8502, Japan
  • Matsumoto, Nagano 390-8621, Japan
  • Hirakata, Osaka 573-1191, Japan
  • Moriguchi, Osaka 570-8507, Japan
  • Osakasayama, Osaka 589-8511, Japan
  • Takatsuki, Osaka 569-1096, Japan
  • Otsu, Shiga 520-2192, Japan
  • Chiyoda-ku, Tokyo 101-8309, Japan
  • Chuoku, Tokyo 104-8560, Japan
  • Hachioji, Tokyo 193-0998, Japan
  • Mitaka, Tokyo 181-8611, Japan
  • Shinjuku-ku, Tokyo 160-0023, Japan
  • Shinjuku-ku, Tokyo 162-8666, Japan
  • Taito-ku, Tokyo 111-0051, Japan
  • Shimonoseki, Yamaguchi 750-0061, Japan
  • Ube, Yamaguchi 755-8505, Japan
  • Chuo, Yamanashi 409-3898, Japan
  • Fukuoka, 812-8582, Japan
  • Fukuoka, 814-0180, Japan
  • Miyazaki, 889-1692, Japan
  • Okayama, 700-8558, Japan
  • Osaka, 533-0024, Japan
  • Osaka, 545-8586, Japan
09

References and documents

Publications

  • Okada AA, Takahashi K, Ohji M, Moon SC, Machewitz T, Sasaki K; ALTAIR Study Investigators. Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in the ALTAIR Study: 96-Week Outcomes in the Polypoidal Choroidal Vasculopathy Subgroup. Adv Ther. 2022 Jun;39(6):2984-2998. doi: 10.1007/s12325-022-02162-w. Epub 2022 May 3. PubMed 35503499 ↗
  • Ohji M, Okada AA, Sasaki K, Moon SC, Machewitz T, Takahashi K; ALTAIR Investigators. Relationship between retinal fluid and visual acuity in patients with exudative age-related macular degeneration treated with intravitreal aflibercept using a treat-and-extend regimen: subgroup and post-hoc analyses from the ALTAIR study. Graefes Arch Clin Exp Ophthalmol. 2021 Dec;259(12):3637-3647. doi: 10.1007/s00417-021-05293-y. Epub 2021 Jul 20. Erratum In: Graefes Arch Clin Exp Ophthalmol. 2022 Jul;260(7):2395-2396. doi: 10.1007/s00417-022-05621-w. PubMed 34283294 ↗
  • Ohji M, Takahashi K, Okada AA, Kobayashi M, Matsuda Y, Terano Y; ALTAIR Investigators. Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in Exudative Age-Related Macular Degeneration: 52- and 96-Week Findings from ALTAIR : A Randomized Controlled Trial. Adv Ther. 2020 Mar;37(3):1173-1187. doi: 10.1007/s12325-020-01236-x. Epub 2020 Feb 3. PubMed 32016788 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2014 to primary completion in Dec 2016, 24 months.

Results were first posted in Mar 2018, 1 year 2 months after primary completion.

Of 12 phase 4 interventional studies under Wet Macular Degeneration, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 38. This study's 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 28, 2014
First posted
Dec 2, 2014
StartActual
Dec 19, 2014
Primary completionActual
Dec 22, 2016
CompletionActual
Dec 20, 2017
Results first posted
Mar 12, 2018
Last update
Nov 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02305238
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Dec 2, 2014
Start date
Dec 19, 2014
Primary completion
Dec 22, 2016
Completion
Dec 20, 2017
Results posted
Mar 12, 2018
Last update
Nov 18, 2023

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aflibercept

Start the discussion